Anti-tumor necrosis factor-alpha monoclonal antibody treatment in a case with persistent juvenile ankylosing spondylitis and inflammatory bowel disease
Articles > Article · 2003
Authors: Can Öztürk, Ferah Genel, Güzide AKSU, Ali Rahmi Bakiler, Necil KÜTÜKÇÜLER
COCUK SAGLIGI VE HASTALIKLARI DERGISI, Journal Indexed in SCI Expanded, International, Scopus, 2003, vol 46, pp 203-206
Summary
Juvenile ankylosing spondylitis and inflammatory bowel disease rarely develop simultaneously, and the treatment of the disease with disease-modifying antirheumatic drugs might be difficult. In this report we present an eight-year old boy with juvenile ankylosing spondylitis and inflammatory bowel disease resistant to combined therapy of antirheumatismal drugs because of its rarity in childhood. Anti-tumor necrosis factor-α monoclonal antibody administration, a new biological treatment, is discussed in view of the literature.